BCDA - BioCardia, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
8.63
+0.38 (+4.61%)
At close: 3:35PM EDT
Stock chart is not supported by your current browser
Previous Close8.25
Open8.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range8.50 - 8.63
52 Week Range8.10 - 32.22
Volume1,157
Avg. Volume444
Market Cap41.838M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-3.19
Earnings DateMar 22, 2019 - Mar 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery

    BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the China National Intellectual Property Administration has recently issued the Company Patent No: ZL 2014 8 00125575 for “Target Site Selection, Entry and Update with Automatic Image Annotation,” with a term to January 7, 2034. The patent describes the use of software that merges images from magnetic resonance imaging (MRI) or computed tomography (CT) with fluoroscopic imaging to plan, document and deliver cell, gene, protein and other therapies using interventional catheter systems. The Company has patents pending for image-guided technology in the U.S., Europe and Japan.

  • GlobeNewswirelast month

    BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange

    BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that a reverse stock split of its common stock, $0.001 par value, at a ratio of one-for-nine, is effective today, June 6, 2019.  The Company’s common stock will begin trading on a split adjusted basis when the markets open under the new trading symbol (BCDAD) and in 20 business days, the trading symbol will revert back to our existing symbol, “BCDA”.  The Company’s common stock has been assigned a new CUSIP number of 09060U507 in connection with the reverse stock split. As a result of the reverse split, each nine pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 43.6 million shares to approximately 4.8 million shares.  The reverse stock split will also apply to common stock issuable upon the exercise of the Company’s outstanding stock options and warrants for common stock.  There is no change to the number of authorized shares under the Company’s Certificate of Incorporation, as amended.  The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable.  The reverse stock split will not affect the par value of the common stock.

  • GlobeNewswire2 months ago

    Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia’s Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class

    BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive results from a study of the company’s Helix™ Biotherapeutic Delivery System for cell therapy used to treat patients early following acute myocardial infarction (AMI) to prevent long term heart failure.

  • GlobeNewswire2 months ago

    BioCardia Reports 2019 First Quarter Financial Results and Business Highlights

    SAN CARLOS, Calif., May 20, 2019 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.

  • GlobeNewswire2 months ago

    BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transseptal Access to Heart

    SAN CARLOS, Calif., May 08, 2019 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.

  • Business Wire4 months ago

    BioCardia Reports 2018 Financial Results and Recent Business Highlights

    BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018, filed its annual 10-K with the Securities and Exchange Commission, and shared recent business highlights.

  • GlobeNewswire5 months ago

    Predictive Technology Group Names Jay M. Moyes to Its Board of Directors

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. “We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group.

  • Business Wire7 months ago

    BioCardia Submits 510(k) Application to FDA for AVANCE Steerable Introducer for Transseptal Access to Heart

    BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced its 510 submission for U.S. Food and Drug Administration clearance of the AVANCE™ steerable introducer, designed for introducing various cardiovascular catheters into the heart, including via the left side of the heart through the interatrial septum.

  • Business Wire8 months ago

    Positive 12-Month Data on BioCardia’s Investigational CardiAMP Cell Therapy System for Heart Failure Presented at American Heart Association Scientific Sessions 2018

    BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive 12 month data for the roll-in cohort of its pivotal CardiAMP™ Heart Failure Trial studying the investigational CardiAMP Cell Therapy System in adult patients experiencing heart failure following a heart attack. The results were presented today by Peter Johnston, MD, of Johns Hopkins Medical Center at the American Heart Association Scientific Sessions 2018. CardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally-invasive, catheter-based procedure to potentially stimulate the body’s natural healing response.

  • Business Wire8 months ago

    BioCardia Reports Third Quarter 2018 Financial Results and Business Highlights

    BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the third quarter 2018 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2018 with the Securities and Exchange Commission.

  • Business Wire8 months ago

    BioCardia Welcomes Cardiovascular Device Veteran Mark Schwartz as Vice President of Clinical Affairs

    BioCardia® [OTC: BCDA] today announced that Mark Schwartz, a 25-year veteran of cardiovascular device development, has joined the company as Vice President of Clinical Affairs, effective November 1. Schwartz brings extensive leadership experience in the design and execution of clinical studies for medical devices in the heart leading to regulatory approvals for such industry leaders as Boston Scientific, The Sorin Group and Guidant, among others. Schwartz comes to BioCardia from EBR Systems, where he served as Vice President of Clinical and Regulatory Affairs for the developer of cardiac resynchronization therapy.

  • Business Wire9 months ago

    BioCardia and CellProThera Partner for Clinical Trial and Marketing in Singapore of Early Stem Cell Therapy for Patients Following Myocardial Infarction

    CellProThera® and BioCardia® today announced an agreement to expand their current collaboration to the SIngXpand Clinical Trial in Singapore. The study will evaluate the safety and efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process and delivered via BioCardia’s Helix™ Biotherapeutic Delivery System for the treatment of patients soon ...

  • PR Newswire10 months ago

    Positive Data On BioCardia's Investigational CardiAMP Cell Therapy For Heart Failure Presented At Transcatheter Cardiovascular Therapeutics (TCT) Conference

    SAN DIEGO and SAN CARLOS, Calif., Sept. 24, 2018 /PRNewswire/ -- BioCardia®, Inc. (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that positive data from two studies of its investigational CardiAMP stem cell therapy were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference. CardiAMP cell therapy uses a patient's own (autologous) bone marrow cells to potentially stimulate the body's natural healing response through a minimally-invasive, catheter-based procedure. Nine month results from the 10-patient roll-in cohort of the CardiAMP Heart Failure Trial, a Phase III pivotal trial, showed clinically meaningful improvements in symptoms, quality of life and exercise capacity, as measured by New York Heart Association class, Minnesota Living with Heart Failure Questionnaire and Six Minute Walk Distance, respectively.

  • PR Newswire10 months ago

    BioCardia Receives Two New U.S. Patents

    U.S. Patent No. 10,035,982 relates to methods of preparing culture-expanded cells for the treatment of heart failure. The patent has broad claims on an approach for expanding mesenchymal stem cells in media derived from the blood of the same donor who has provided the source cells for culture expansion. In the patented method, a single donor provides the source cells for expansion of the targeted stem cells and blood over time to produce a donor-specific culture medium.

  • PR Newswire10 months ago

    Additional Results From BioCardia's Phase III Pivotal CardiAMP Heart Failure Trial To Be Presented At Three Influential Fall Cardiovascular Congresses

    SAN CARLOS, Calif. , Sept. 5, 2018 /PRNewswire/ --  BioCardia® , Inc. (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that ...

  • PR Newswire11 months ago

    Preliminary Results From BioCardia's Phase III Pivotal CardiAMP Heart Failure Trial Reported In Circulation Research Journal

    The company believes this to be the first outcomes data published from any pivotal trial of a stem cell therapy for heart failure. The paper is authored by Peter Johnston, M.D., Eric Duckers, M.D., Ph.D., Amish Raval, M.D., Thomas Cook, Ph.D. and Carl Pepine, M.D.

  • PR Newswire11 months ago

    BioCardia, Inc. Reports Second Quarter 2018 Financial Results and Business Highlights

    SAN CARLOS, Calif. , Aug. 9, 2018 /PRNewswire/ --  BioCardia®, Inc.  , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial ...